Diversified Trust Co Makes New Investment in GSK PLC Sponsored ADR (NYSE:GSK)

Diversified Trust Co purchased a new position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 9,644 shares of the pharmaceutical company's stock, valued at approximately $374,000.

A number of other hedge funds have also bought and sold shares of the company. Total Wealth Planning & Management Inc. grew its stake in GSK by 46.5% in the first quarter. Total Wealth Planning & Management Inc. now owns 16,881 shares of the pharmaceutical company's stock worth $654,000 after purchasing an additional 5,356 shares in the last quarter. PDS Planning Inc bought a new position in GSK in the first quarter worth about $242,000. Sequoia Financial Advisors LLC lifted its holdings in GSK by 12.8% in the first quarter. Sequoia Financial Advisors LLC now owns 23,294 shares of the pharmaceutical company's stock worth $902,000 after acquiring an additional 2,649 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in GSK by 100.3% in the first quarter. Golden State Wealth Management LLC now owns 2,277 shares of the pharmaceutical company's stock worth $88,000 after acquiring an additional 1,140 shares during the last quarter. Finally, First Pacific Financial bought a new position in GSK in the first quarter worth about $45,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Price Performance

Shares of NYSE GSK traded down $0.43 during mid-day trading on Wednesday, reaching $38.52. 4,878,727 shares of the company traded hands, compared to its average volume of 4,925,969. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $44.67. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58. The firm has a market cap of $78.86 billion, a PE ratio of 19.86, a price-to-earnings-growth ratio of 1.36 and a beta of 0.50. The stock has a fifty day simple moving average of $38.94 and a 200-day simple moving average of $37.02.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The business had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same quarter last year, the business earned $0.43 earnings per share. The business's revenue for the quarter was up 2.1% on a year-over-year basis. Equities research analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be paid a dividend of $0.4216 per share. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.38%. The ex-dividend date of this dividend is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is currently 87.11%.

Analysts Set New Price Targets

GSK has been the topic of a number of recent analyst reports. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. BNP Paribas initiated coverage on GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target on the stock. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Finally, Hsbc Global Res raised GSK to a "strong sell" rating in a report on Monday, April 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.